Type 2 Diabetes News and Research RSS Feed - Type 2 Diabetes News and Research

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.
Drinking coffee increases risk of cardiovascular events in young adults with mild hypertension

Drinking coffee increases risk of cardiovascular events in young adults with mild hypertension

Coffee drinking is associated with increased risk of cardiovascular events (mainly heart attacks) in young adults (18-45) with mild hypertension, according to research presented at ESC Congress today by Dr Lucio Mos, a cardiologist at Hospital of San Daniele del Friuli in Udine, Italy. [More]
Research with UWF imaging may change how diabetic eye disease is assessed and treated

Research with UWF imaging may change how diabetic eye disease is assessed and treated

For decades, clinicians have detected and monitored diabetic eye disease with standard retinal photographs that cover about a third of the retina. In recent years, an emerging class of ultrawide field (UWF) cameras has given a substantially larger view of the retina, providing new insight on the presentation and natural history of retinal disease. [More]
Key modifiable Alzheimer’s risk factors pinpointed

Key modifiable Alzheimer’s risk factors pinpointed

A meta-analysis has identified the key modifiable factors associated with an increased or decreased risk of Alzheimer’s disease. [More]
Potential biomarker could help prevent pre-diabetic individuals from developing Type II diabetes

Potential biomarker could help prevent pre-diabetic individuals from developing Type II diabetes

Virginia Tech researchers have identified a biomarker in pre-diabetic individuals that could help prevent them from developing Type II diabetes. [More]
EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. [More]
New genome-wide association study sheds light on the underlying biology of polycystic ovary syndrome

New genome-wide association study sheds light on the underlying biology of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) has been passed down in many families for generations -- causing reproductive and metabolic health problems for millions of women around the world. Yet, its cause remains unknown despite more than 80 years of research since the disorder was first described in 1935. [More]
Discovery could influence future research on respiratory failure associated with diabetes

Discovery could influence future research on respiratory failure associated with diabetes

Previous studies have shown that diabetes adversely affects breathing and respiratory function. However, in the past, researchers have not differentiated diaphragm muscle cells and the muscle cells of limb skeletal muscle in their studies. Now, researchers from the University of Missouri have found that diaphragm muscle cells and other skeletal muscle cells behave differently--a finding that could influence future research on respiratory ailments associated with diabetes. [More]
Common diabetes drug metformin works in gut, not the bloodstream

Common diabetes drug metformin works in gut, not the bloodstream

Although metformin was introduced as a treatment for type 2 diabetes nearly 60 years ago and is now the recommended first-line treatment for newly diagnosed patients, researchers still debate precisely how the drug works. [More]
Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA. [More]
Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment. [More]
FSU study reveals new method for treating diabetes

FSU study reveals new method for treating diabetes

A new Florida State University study is changing how researchers look at diabetes research and the drugs used to treat the disease. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
Low-fat diets better than low-carb diets for weight loss, NIH study finds

Low-fat diets better than low-carb diets for weight loss, NIH study finds

In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets. Carb restriction lowered production of the fat-regulating hormone insulin and increased fat burning as expected, whereas fat restriction had no observed changes in insulin production or fat burning. [More]
High-protein breakfast prevents body fat gains, stabilizes glucose levels among overweight teens

High-protein breakfast prevents body fat gains, stabilizes glucose levels among overweight teens

Approximately 60 percent of young people habitually skip breakfast up to four times a week, previous research has shown. Although health experts recommend breakfast as a strategy to reduce an individual's chance of obesity, little research has examined if the actual type of breakfast consumed plays a significant role in one's health and weight management. [More]
Common marker can help identify patients at high risk for deadly cardiac events

Common marker can help identify patients at high risk for deadly cardiac events

A marker commonly used to determine if a patient is having a heart attack can also be used to identify stable patients at high risk for deadly cardiac events, according to a new study led by investigators at Brigham and Women's Hospital. [More]
Saturated fats may not be so bad for our health after all

Saturated fats may not be so bad for our health after all

A study led by scientists at McMaster University has found that saturated fats may not be as bad for our health as previously thought. [More]
Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels. [More]
Trans fats associated with greater risk of death, coronary heart disease

Trans fats associated with greater risk of death, coronary heart disease

A study led by researchers at McMaster University has found that that trans fats are associated with greater risk of death and coronary heart disease, but saturated fats are not associated with an increased risk of death, heart disease, stroke, or Type 2 diabetes. [More]
BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

BIDMC scientists discover new vitamin B3 pathway that regulates liver metabolism

Researchers at Beth Israel Deaconess Medical Center have identified a new vitamin B3 pathway that regulates liver metabolism. The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases. [More]
Metformin drug has impact on blood fat levels

Metformin drug has impact on blood fat levels

Besides affecting the blood sugar levels, the substance Metformin, also has an impact on blood fat levels. This was elucidated by an interdisciplinary team of the German Center for Diabetes Research headed by Dr. Rui Wang-Sattler of the Helmholtz Zentrum München. Especially the harmful LDL cholesterol can be reduced. [More]
Advertisement
Advertisement